quinazolines has been researched along with cladribine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertele', V; Garattini, S; Gerardi, C; Joppi, R | 1 |
| Li, Y; Liu, D; Quan, Y; Wu, B; Wu, Y; Zhang, D; Zhang, X | 1 |
1 review(s) available for quinazolines and cladribine
| Article | Year |
|---|---|
Letting post-marketing bridge the evidence gap: the case of orphan drugs.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Barrett Esophagus; Cladribine; Dihematoporphyrin Ether; Ductus Arteriosus, Patent; Hepatolenticular Degeneration; Humans; Ibuprofen; Leukemia, Hairy Cell; Mitotane; Orphan Drug Production; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Quinazolines; Thrombocythemia, Essential; Zinc Acetate | 2016 |
1 other study(ies) available for quinazolines and cladribine
| Article | Year |
|---|---|
Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cladribine; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; MCF-7 Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |